Chang C. Liu

Chang C. Liu

Auto-generated profile, based on publicly available information

Chang C. Liu

Department of Biomedical Engineering, University of California, Irvine, Irvine, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2010 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
CLChang C. Liu
Chang C. Liu
PSPeter G. Schultz
Peter G. Schultz
The development of new orthogonal aminoacyl-tRNA synthetase/tRNA pairs has led to the addition of approximately 70 unnatural amino acids (UAAs) to the genetic codes of Escherichia coli, yeast, and mammalian cells. These UAAs represent a wide range of structures and functions not found in the canonical 20 amino acids and thus provide new opportunities to generate proteins with enhanced or novel properties and probes of protein structure and function.

1 December 2018 in Cell
Verified
Journal Article
Closed access
ARArjun Ravikumar
Arjun Ravikumar
GAGarri A. Arzumanyan
Garri A. Arzumanyan
MOMuaeen K.A. Obadi
Muaeen K.A. Obadi
AJAlex A. Javanpour
Alex A. Javanpour
CLChang C. Liu
Chang C. Liu

3 July 2015 in Science Advances
Verified
Journal Article
Open access
PDF file
RPRory N. Pruitt
Rory N. Pruitt
BSBenjamin Schwessinger
Benjamin Schwessinger
AJAnna Joe
Anna Joe
NTNicholas Thomas
Nicholas Thomas
FLFurong Liu
Furong Liu
PRPamela C. Ronald
Pamela C. Ronald
Surveillance of the extracellular environment by immune receptors is of central importance to eukaryotic survival. The rice receptor kinase XA21, which confers robust resistance to most strains of the Gram-negative bacterium Xanthomonas oryzae pv. oryzae (Xoo), is representative of a large class of cell surface immune receptors in plants and animals. We report the identification of a previously undescribed Xoo protein, called RaxX, which is required for activation of XA21-mediated immunity. Xoo strains that lack RaxX, or carry mutations in the single RaxX tyrosine residue (Y41), are able to evade XA21-mediated immunity. Y41 of RaxX is sulfated by the prokaryotic tyrosine sulfotransferase RaxST. Sulfated, but not nonsulfated, RaxX triggers hallmarks of the plant immune response in an XA21-dependent manner. A sulfated, 21–amino acid synthetic RaxX peptide (RaxX21-sY) is sufficient for this activity. Xoo field isolates that overcome XA21-mediated immunity encode an alternate raxX allele, suggesting that coevolutionary interactions between host and pathogen contribute to RaxX diversification. RaxX is highly conserved in many plant pathogenic Xanthomonas species. The new insights gained from the discovery and characterization of the sulfated protein, RaxX, can be applied to the development of resistant crop varieties and therapeutic reagents that have the potential to block microbial infection of both plants and animals.

5 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
NBNathaniel R. Bennett
Nathaniel R. Bennett
JWJoseph L. Watson
Joseph L. Watson
RRRobert J. Ragotte
Robert J. Ragotte
ABAndrew J. Borst
Andrew J. Borst
DSDéjenaé L. See
Déjenaé L. See
DBDavid Baker
David Baker
Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization, random library screening or the isolation of antibodies directly from patients1. Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion2 network with yeast display screening enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable fragments (scFvs) and full antibodies that bind to user-specified epitopes with atomic-level precision. We experimentally characterize VHH binders to four disease-relevant epitopes. Cryo-electron microscopy confirms the binding pose of designed VHHs targeting influenza haemagglutinin and Clostridium difficile toxin B (TcdB). A high-resolution structure of the influenza-targeting VHH confirms atomic accuracy of the designed complementarity-determining regions (CDRs). Although initial computational designs exhibit modest affinity (tens to hundreds of nanomolar Kd), affinity maturation using OrthoRep3 enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of scFvs to TcdB and a PHOX2B peptide–MHC complex by combining designed heavy-chain and light-chain CDRs. Cryo-electron microscopy confirms the binding pose for two distinct TcdB scFvs, with high-resolution data for one design verifying the atomically accurate design of the conformations of all six CDR loops. Our approach establishes a framework for the computational design, screening and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.

2 February 2014 in Nature Chemical Biology
Verified
Journal Article
Closed access
ARArjun Ravikumar
Arjun Ravikumar
AAAdrian Arrieta
Adrian Arrieta
CLChang C Liu
Chang C Liu

18 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNathaniel R. Bennett
Nathaniel R. Bennett
JWJoseph L. Watson
Joseph L. Watson
RRRobert J. Ragotte
Robert J. Ragotte
ABAndrew J. Borst
Andrew J. Borst
DSDéjenaé L. See
Déjenaé L. See
DBDavid Baker
David Baker
Despite the central role that antibodies play in modern medicine, there is currently no method to design novel antibodies that bind a specific epitope entirely in silico . Instead, antibody discovery currently relies on animal immunization or random library screening approaches. Here, we demonstrate that combining computational protein design using a fine-tuned RFdiffusion network alongside yeast display screening enables the generation of antibody variable heavy chains (VHHs) and single chain variable fragments (scFvs) that bind user-specified epitopes with atomic-level precision. To verify this, we experimentally characterized VHH binders to four disease-relevant epitopes using multiple orthogonal biophysical methods, including cryo-EM, which confirmed the proper Ig fold and binding pose of designed VHHs targeting influenza hemagglutinin and Clostridium difficile toxin B (TcdB). For the influenza-targeting VHH, high-resolution structural data further confirmed the accuracy of CDR loop conformations. While initial computational designs exhibit modest affinity, affinity maturation using OrthoRep enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of single-chain variable fragments (scFvs), creating binders to TcdB and a Phox2b peptide-MHC complex by combining designed heavy and light chain CDRs. Cryo-EM structural data confirmed the proper Ig fold and binding pose for two distinct TcdB scFvs, with high-resolution data for one design additionally verifying the atomically accurate conformations of all six CDR loops. Our approach establishes a framework for the rational computational design, screening, isolation, and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.